News stories on health policy developments from the Hill and their effect on the pharmaceutical industry
February 1, 2012
By:Jill Wechsler
Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?
 |
January 1, 2012
By:Jill Wechsler
Look for action in 2012 on drug access, shortages, innovation, and transparency.
|
December 1, 2011
By:Jill Wechsler
Agency expansion and globalization promote innovation, collaboration, and organizational changes
|
November 1, 2011
By:Jill Wechsler
Clamor for critical therapies prompts probes of prices, production practices.
|
September 1, 2011
By:Jill Wechsler
User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.
|
August 1, 2011
By:Jill Wechsler
A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation
|
July 1, 2011
By:Jill Wechsler
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
|
June 1, 2011
By:Jill Wechsler
FDA's opiod REMS implies there is still value in industry-sponsored CME
|
May 1, 2011
By:Jill Wechsler
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
